Reasons of lost to follow-up and clinical characteristics of Familial Mediterranean fever patients
PDF
Cite
Share
Request
Original Article
E-PUB
12 March 2026

Reasons of lost to follow-up and clinical characteristics of Familial Mediterranean fever patients

J Turk Soc Rheumatol. Published online 12 March 2026.
1. Sağlık Bilimleri Üniversitesi, Gülhane Eğitim ve Araştırma Hastanesi, İç Hastalıkları Anabilim Dalı, Romatoloji Bilim Dalı, Ankara, Türkiye
2. Sağlık Bilimleri Üniversitesi, Gülhane Eğitim ve Araştırma Hastanesi, İç Hastalıkları Anabilim Dalı, Ankara, Türkiye
3. Ankara Eğitim ve Araştırma Hastanesi, Tıbbi Biyokimya Kliniği, Ankara, Türkiye
No information available.
No information available
Received Date: 18.06.2024
Accepted Date: 23.11.2025
E-Pub Date: 12.03.2026
PDF
Cite
Share
Request

Abstract

Objective

Familial Mediterranean fever (FMF), which is common in countries neighbouring the Mediterranean, requires regular follow-up like other chronic inflammatory rheumatological diseases. Deficiencies in the treatment and follow-up of the disease may result in significant morbidity.In this study, we investigated the reasons for non-follow-up of FMF patients and the clinical characteristics of these patients.

Methods

FMF patients who had not attended rheumatology control for more than 1 year were included in this study. Patients were telephoned and asked the reasons of lost to follow-up. Clinical and demographic characteristics of the patients were recorded. Modified Morinsky scale (MMS)-motivation and MMS-knowledge level questionnaires were applied for treatment compliance. Comparison was made between the patients with no follow-up and those with follow-up at an external centre. Comparison of the patient groups with follow-up and those without follow-up was made. P<0.05 was considered statistically significant.

Results

It was learnt that  of the 176 patients who could be contacted by phone, 74 (42.1%) patients were followed-up in external centres and 93 patients were lost to follow-up. Most of the patients lost to follow-up were university graduates (48.1%) and high school graduates (31.2%). The most common reasons of lost to follow-up were negligence (28%) and failure to find an appointment (25.8%). The variables of MMS-motivation, MMS-knowledge level and informing patients about the need for follow-up at diagnosis had a significant relationship with non-follow-up (p<0.05).

Conclusion

The fact that “negligence” was found to be the most common reason of lost to follow-up despite the high educational status of FMF patients revealed the importance of informing even educated patients about the necessity of follow-up. This was supported by the fact that the MMS-motivation and MMS-knowledge level scores were low in patients lost to follow-up. In addition, setting the green list registrations as indefinite will reduce patients’ loss of follow-up.

Keywords:
Familial Mediterranean fever, reasons for patients lost to follow-up, characteristics of patients lost to follow-up

References

1
Goldfinger SE. Colchicine for familial Mediterranean fever. N Engl J Med. 1972;287:1302.
2
Van Cutsem G, Ford N, Hildebrand K, et al. Correcting for mortality among patients lost to follow up on antiretroviral therapy in South Africa: a cohort analysis. PLoS One. 2011;6:e14684.
3
Tien YC, Chiu YM, Liu MP. Frequency of lost to follow-up and associated factors for patients with rheumatic diseases. PLoS One. 2016;11:e0150816.
4
Foocharoen C, Yenrom P, Mahakkanukrauh A, Suwannaroj S, Nanagara R. Prevalence and causes of loss to follow-up among patients with systemic sclerosis. J Clin Rheumatol. 2014;20:456.
5
Familial Mediterranean fever (FMF) in Turkey: results of a nationwide multicenter study. Medicine (Baltimore). 2005;84:1-11.
6
Vural B, Acar ÖT, Topsever P, Filiz TM. Reliability and validity of Turkish version of modified Morisky scale. J Turk Fam Physician. 2012;3:17-20.
7
Esatoğlu SN, Çelik F, Yeşilsancak M, Doymaz F, Uğurlu S. Frequency of lost to follow-up of rheumatoid arthritis and ankylosing spondylitis patients in a tertiary center. J Turk Soc Rheumatol. 2020;12:7-11.